(+) Idera Pharma: BIO CEO & Investor Conference (Idera Pharmaceuticals, Inc) - Feb 13, 2013 - "IMO-3100: Proof of Concept Established in Patients with Psoriasis"; "Treatment with IMO-3100 was well tolerated"; "Rapid improvement in Psoriasis Area and Severity Index (PASI) scores in IMO-3100 treated subjects"; "PASI decreased 35% to 90% in half of all IMO-3100 treated patients"; "PASI-50 was achieved in 25% of patients treated with 0.16 mg/kg and in 31% with 0.32 mg/kg"; PASI decrease among patients treated with IMO-3100 at 0.16 mg/kg was statistically significant"; "Significant improvement in plaque induration, a clinical assessment of plaque thickness, at 0.16 mg/kg dose"
P2 data • Psoriasis
|